Trump announces trade deal with EU following months of negotiations
Medirom Healthcare Technologies Inc . (NASDAQ:MRM), currently trading at $52.93 and showing strong financial health according to InvestingPro analysis, announced Monday that its board of directors has approved the issuance of new stock options under its 2024 Equity Incentive Compensation Plan, according to a statement based on an SEC filing.
The stock options are scheduled to be granted on or around July 18, 2025, following the expected execution of allotment agreements by recipients on or around July 7, 2025. Each option will allow the holder to purchase one share of common stock, with an issue price of ¥2 per option.
The exercise price per share is set at $1.74, but if the closing price of Medirom’s American Depositary Shares on Nasdaq on the allotment date is lower, that price will be used instead.
The options will be exercisable from July 18, 2026, through July 17, 2030, but only if certain conditions are met. One key condition requires that, in any fiscal year from 2026 through 2028, the company’s adjusted consolidated revenues—excluding revenue from Digital Preventative Healthcare and sales of directly-owned salons—must exceed JPY10 billion at least once. According to the company, this would require an increase of approximately 69% from the amount reported for the fiscal year ended December 31, 2024.
Recipients must also be directors, statutory auditors, employees, or external collaborators of Medirom or its affiliates at the time of exercise. If a recipient leaves the company, the options may be exercised within 12 months of departure, except in cases such as expiration of tenure or retirement age, as determined by the board.
The options will be allotted as follows: 207,000 to directors and statutory auditors (14 individuals), 87,000 to employees (16 individuals), and 106,000 to external collaborators (7 individuals).
The stock options are subject to forfeiture under certain conditions, including dismissal for cause, and may be adjusted in the event of a stock split or reverse split.
All information is based on a press release statement included in the company’s filing with the Securities and Exchange Commission. For comprehensive analysis of Medirom’s financial health, growth prospects, and detailed valuation metrics, investors can access the full Pro Research Report available on InvestingPro, which covers over 1,400 US-listed companies with expert insights and actionable intelligence.
In other recent news, ON Semiconductor (NASDAQ:ON) has been the focus of multiple analyst assessments. Mizuho (NYSE:MFG) raised its price target for the company to $72.00, maintaining an Outperform rating, citing strong positioning in the automotive sector, particularly in electric vehicles and advanced driver assistance systems. However, Cantor Fitzgerald initiated coverage with a neutral rating and a $55.00 price target, expressing concerns about ON Semiconductor’s exposure to the automotive market and suggesting that the company’s structural transformation will require time. Mizuho also highlighted potential risks related to Section 232 regulations that could impact the sector in the near term.
VEON Ltd (AS:VON). released its unaudited interim financial statements for the first quarter of 2025, providing updated financial performance details. The filing was made with the U.S. Securities and Exchange Commission as part of its regulatory requirements. Meanwhile, MINISO Group Holding Limited submitted several disclosure returns to the SEC, detailing changes in its issued share capital, in compliance with regulatory standards for transparency. These recent developments reflect ongoing activities and assessments in the respective companies’ operations and market positions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.